ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för SF2523. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 2023-04-27

LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies.

Bala V, Chhonker YS, Morales GA, Maddeboina K, Pal D, Durden DL, Murry DJ.

Biomed Chromatogr · research-article; journal article · DOI 10.1002/bmc.5643

Bibliografisk träff 2023-01-05

Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma.

Sethi B, Kumar V, Jayasinghe TD, Dong Y, Ronning DR, Zhong HA, Coulter DW, Mahato RI.

J Control Release · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jconrel.2022.12.055

Bibliografisk träff 2022-05-23

Promoting autophagy to mitigate coronavirus disease pathology in the elderly.

Lund Da Costa A, Mehta H, Mathur R.

Clin Transl Discov · article-commentary; journal article · DOI 10.1002/ctd2.68

Bibliografisk träff 2022-05-06

Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS-CoV-2 infection.

Acharya A, Kutateladze TG, Byrareddy SN.

Clin Transl Discov · article-commentary; journal article · DOI 10.1002/ctd2.66

Bibliografisk träff 2021-12-01

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia.

Ruan Y, Kim HN, Ogana HA, Wan Z, Hurwitz S, Nichols C, Abdel-Azim N, Coba A, Seo S, Loh YE, Gang EJ, Abdel-Azim H, Hsieh CL, Lieber MR, Parekh C, Pal D, Bhojwani D, Durden DL, Kim YM.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.766888

Bibliografisk träff 2021-09-29

Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.

Kumar V, Wang Q, Sethi B, Lin F, Kumar V, Coulter DW, Dong Y, Mahato RI.

Biomaterials · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.biomaterials.2021.121138

Bibliografisk träff 2021-04-01

Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.

Goldin AN, Singh A, Joshi S, Jamieson C, Durden DL.

J Pediatr Hematol Oncol · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1097/mph.0000000000002054

Bibliografisk träff 2019-04-24

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.

Joshi S, Singh AR, Liu KX, Pham TV, Zulcic M, Skola D, Chun HB, Glass CK, Morales GA, Garlich JR, Durden DL.

Mol Cancer Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-18-1206

Bibliografisk träff 2019-02-26

SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.

Zhu JX, Xiao JR.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2019.02.080

Bibliografisk träff 2018-02-23

Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.

Campbell GR, Bruckman RS, Herns SD, Joshi S, Durden DL, Spector SA.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.ra118.002353

Bibliografisk träff 2017-12-10

A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.

Su J, Liu X, Zhang S, Yan F, Zhang Q, Chen J.

Chem Biol Drug Des · research support, non-u.s. gov't; journal article · DOI 10.1111/cbdd.13148

Bibliografisk träff 2017-11-10

Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.

Shen G, Jiang M, Pu J.

Biochem Biophys Res Commun · journal article · DOI 10.1016/j.bbrc.2017.11.062

Bibliografisk träff 2017-09-30

Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth.

Zhu H, Mao JH, Wang Y, Gu DH, Pan XD, Shan Y, Zheng B.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.21432

Bibliografisk träff 2017-01-30

Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.

Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR, Durden DL, Kutateladze TG.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1613091114

Bibliografisk träff 2016-09-07

Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.

Carlino L, Rastelli G.

J Med Chem · review; journal article · DOI 10.1021/acs.jmedchem.6b00438

Bibliografisk träff 2013-02-27

Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.

Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL.

J Med Chem · journal article · DOI 10.1021/jm301522m